Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Janet Griffiths"'
Autor:
Jonathan Corren, Andrew Lindsley, Joseph Spahn, Bill Cook, Janet Griffiths, Nicole Martin, Gene Colice, Ian Pavord
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a16560b1f604094010ac49fdbca8201
https://doi.org/10.1016/j.jaci.2022.12.606
https://doi.org/10.1016/j.jaci.2022.12.606
Autor:
Janet Griffiths, Tuyet-Hang Pham, Eileen Wang, Chris Ambrose, Neil Martin, Jane Parnes, Andrew Lindsley, Gillian Hunter, Gene Colice, John Oppenheimer
Publikováno v:
Journal of Allergy and Clinical Immunology. 149:AB14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6aa2a57b2a9bd51a05f13fd9a776f53
https://doi.org/10.1016/j.jaci.2021.12.085
https://doi.org/10.1016/j.jaci.2021.12.085
Autor:
Sean Turman, Benjamin Kemp, Ronald Herbst, Janet Griffiths, Jennifer Cann, Mary Jane Hinrichs, M. Jack Borrok, Lisa Marie Kitching Vinall, D. Gareth Rees, David Howe, Yue Wang, Carlos Gonzalez, Shu Wang, Steven Eck, Hong Sun, Brian Naiman, Katherine A. Vousden, Koshu Okubo, Roland Kolbeck, Antonio DiGiandomenico, Tanya N. Mayadas, Gary P. Sims, Ethan Grant, Neang Ly, Ximing Xiong, Yebin Zhou, Srinath Kasturiangan, Holly Koelkebeck, Weiguang Zhao, Christopher Morehouse, Bo Chen
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveImmune complexes (ICs) play a critical role in the pathology of autoimmune diseases. The aim of this study was to generate and characterise a first-in-class anti-FcγRIIA antibody (Ab) VIB9600 (previously known as MEDI9600) that blocks IgG i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7db10d8acb51c551c5223d6a8f518b5
http://europepmc.org/articles/PMC6352406
http://europepmc.org/articles/PMC6352406
Autor:
Janet Griffiths, Stephanie L. Roseti, May Mo, Liangwei Wang, Jonathan Corren, Jane R. Parnes, René van der Merwe
Publikováno v:
New England Journal of Medicine. 377:936-946
In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24f619be427be4d806dfe13f2e875040
https://doi.org/10.1056/nejmoa1704064
https://doi.org/10.1056/nejmoa1704064
Autor:
Christopher E. Brightling, Gene L. Colice, Sarah Diver, Latifa Chachi, João P Sousa, Paul Newbold, Claire Emson, Gillian Elliott, Janet Griffiths, Richard J. Russell
Publikováno v:
Airway pharmacology and treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f88ed99ba13dfe3f4e9307d9c4e12e91
https://doi.org/10.1183/13993003.congress-2019.pa1660
https://doi.org/10.1183/13993003.congress-2019.pa1660
Autor:
Wendy I. White, Yuling Wu, Jane R. Parnes, Jennifer Kearley, Wei Zhao, Sriram Sridhar, Janet Griffiths, Tuyet-Hang Pham, Lorin Roskos
Publikováno v:
Airway pharmacology and treatment.
Background: Tezepelumab, a human monoclonal antibody that selectively blocks thymic stromal lymphopoietin interaction (TSLP) with its receptor, improved clinical outcomes vs. placebo in patients with severe, uncontrolled asthma (Phase 2b PATHWAY stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbcf4be767617c547e57631f928c01eb
https://doi.org/10.1183/13993003.congress-2019.rct3785
https://doi.org/10.1183/13993003.congress-2019.rct3785
Publikováno v:
B15. IMMUNOTHERAPY FOR LUNG DISEASE.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1b788bca02c2af7fe2446f5902b22ea
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2621
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2621
Publikováno v:
Clinical Problems.
Background: Tezepelumab, a human anti-thymic stromal lymphopoietin monoclonal antibody, has demonstrated efficacy and safety in a placebo-controlled phase 2b dose-ranging study (Corren J et al. NEJM 2017;377:936-46) in adults with severe uncontrolled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e8f9733306ae22eee0db2994fccbd71
https://doi.org/10.1183/13993003.congress-2018.pa1688
https://doi.org/10.1183/13993003.congress-2018.pa1688
Autor:
May Mo, René van der Merwe, Jonathan Corren, Liangwei Wang, Jane R. Parnes, Stephanie L. Roseti, Janet Griffiths
Publikováno v:
Clinical Problems.
Background: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine and key regulator of inflammatory pathways including type 2 responses. Tezepelumab is a human anti-TSLP monoclonal antibody that reduces the early and late phase asthmatic resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a24c6ed753cd4365a51b5f627d365510
https://doi.org/10.1183/1393003.congress-2017.oa3189
https://doi.org/10.1183/1393003.congress-2017.oa3189
Autor:
Shu Wang, Roland Kolbeck, Ronald Herbst, Benjamin Kemp, Gary P. Sims, Steven Eck, Sean Turman, Ximing Xiong, Bo Chen, D. Close, Katherine A. Vousden, S Kasturiangan, Antonio DiGiandomenico, Mary Jane Hinrichs, Hong Sun, Lisa Marie Kitching Vinall, Janet Griffiths, Ethan Grant
Publikováno v:
Oral Presentations.
Background Collectively, the cell surface Fc region of IgG receptors (FcγRs) engage soluble IgG and IgG containing immune complexes and trigger activation or inhibtory signals that play a critical role in the regulation of immune responses. The low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6eec366bf1d15b3fd3953c822e67a25
https://doi.org/10.1136/annrheumdis-2017-eular.1994
https://doi.org/10.1136/annrheumdis-2017-eular.1994